The UK will be transformed into a global hub for radiotherapy research, pioneering the use of the latest techniques such as FLASH radiotherapy and artificial intelligence, with a new £56 million research network announced by Cancer Research UK.
The network, Cancer Research UK RadNet, is the charity's largest ever investment in radiotherapy research and will accelerate the development of advanced radiotherapy techniques, challenging the boundaries of this mainstay treatment through world-first exploratory projects.
It will unite seven centres of excellence across the country: The Universities of Cambridge, Glasgow, Leeds, Manchester and Oxford, the Cancer Research UK City of London Centre (a partnership between UCL, Queen Mary University of London, King's College London the Francis Crick Institute) and The Institute of Cancer Research, London in partnership with The Royal Marsden NHS Foundation Trust.
Michelle Mitchell, chief executive of Cancer Research UK, said: "Radiotherapy is a cornerstone of cancer medicine, with around 3 in 10 patients receiving it as part of their primary treatment. The launch of our network marks a new era of radiotherapy research in the UK. Scientists will combine advances in our understanding of cancer biology with cutting-edge technology to make this treatment more precise and effective than ever before".
Cancer Research UK supported some of the earliest research into radiotherapy, pioneering the use of radium to treat cancer in the 1920s.
Modern radiotherapy works by targeting tumours with x-ray radiation, killing cancer cells by irreversibly damaging their DNA.
Today, over 130,000 patients are treated with radiotherapy on the NHS every year.
Cancer Research UK RadNet aims to improve cancer survival by optimising and personalising radiotherapy.
The centres will spearhead the development of new techniques for delivering radiotherapy and investigate new radiotherapy-drug combinations, including immunotherapies.
Scientists will also focus on reducing the long-term side effects associated with this treatment, improving patients' quality of life during and after treatment.
The innovative research that Cancer Research UK RadNet will deliver includes:
Cancer Research UK RadNet will be a beacon, attracting leading researchers from across the globe to boost radiotherapy research capacity in the UK.
£13 million has been allocated to form new research groups and fund additional PhD students in Manchester, London and Cambridge, ensuring the UK's radiotherapy research community continues to thrive.
The network will promote collaboration between diverse scientific fields, with a share of £4 million available to all centres for joint research projects, conferences and secondments between locations.
Dr Adrian Crellin, Cancer Research UK Trustee and Former Vice-President of the Royal College of Radiologists, said: "I've seen first-hand how successful radiotherapy can be for patients that I treat, but it's been frustrating to see the UK lagging behind other countries when it comes to prioritising research into this vital treatment. Cancer Research UK's investment will overhaul radiotherapy research in the UK to bring the next generation of treatments to patients sooner."
Source: Cancer Research UK
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.